Trial Details
COMPLETEDBasic Information
| Clinical ID | c391 |
|---|---|
| Identifier | NCT05684484 |
| Trial Title | Role of Roflumilast in Ulcerative Colitis |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Ulcerative Colitis |
| Interventions | DRUG: Roflumilast 500 MCG Oral Tablet [DALIRESP]|DRUG: amino salicylic acid |
Participant Information
| Sponsor | Tanta University |
|---|---|
| City | Tanta |
| Country/Region | Egypt |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | CHILD, ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE4 |
Time Information
| Start Date | 2023-02-01 |
|---|---|
| Primary Completion Date | 2024-04-15 |
| Completion Date | 2024-09-15 |